Outsourcing in silico predictive toxicology: Technologies, markets and paradigms

Future Medicinal Chemistry

Volumn 2, Issue 10, 2010, Pages 1507-1510

  Ismail, Alexandre ^a  

^a BioQuanta   (France)

Author keywords

drug development; in silico; outsourcing; predictive toxicology; toxictiy

Indexed keywords

COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; DRUG DEVELOPMENT; DRUG MARKETING; EDITORIAL; GOLD STANDARD; MEDICAL TECHNOLOGY; PREDICTION; PREDICTIVE TOXICOLOGY; PRESCRIPTION; PRIORITY JOURNAL; PRODUCTIVITY; TOXICOLOGY;

COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; OUTSOURCED SERVICES; TOXICOLOGY;

EID: 77958062923     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.242     Document Type: Editorial

References (6)

1. PriceWaterhouseCoopers Analysis. Pharma 2020: The Vision -Which Path Will You Take? PriceWaterhouseCoopers, London, UK, June 2007.
2. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 20(Suppl. 3), 1-10 (2002
3. Guerin GA, Pratuangdejkul J, Alemany M, Launay JM, Manivet P. Rational and efficient geometric defintion of pharmacophores is essential for the patent process. Drug Discov. Today 11(21-22), 991-998 (2006
4. Maggiora GM. On outliers and activity cliffs -why QSAR often disappoints. J. Chem. Inf. Model. 46, 1535 (2006
5. Peters MB, Raha K, Merz KM Jr. Quantum mechanics in structure-based drug design. Curr. Opin. Drug Discov. Devel. 9(3), 370-379 (2006
6. REACH legislation: Annex XV Restriction Report -Proposal for a restriction of dimethyl fumarate -by ANSES (The French agency for food, environmental, and occupational health safety). http://echa.europa.eu/doc/ restrictions/ annex-xv-restriction-report-DMFu-en.pdf